S2X259
An anti-RBD (SARS-CoV-2 Spike) monoclonal antibody.
General information
S2X259 is a human monoclonal antibody recognizing a cryptic epitope within Spike RBD from various sarbecovirus clades including SARS-CoV-2. It inhibits ACE2 binding and has a good escape profile. S2X259 displayed protective effect in an animal challenge (Tortorici et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Spike protein Spike variant Protein factor In vitro Antibody |
Vero E6-TMPRSS2 cells; SARS-CoV-2 Spike-pseudotyped viruses (including WA1/2020 D614G or Omicron) | 49.96 | The antibody neutralizes Omicron variant of SARS-CoV-2 in vitro. |
Dec/23/2021 |
|
Broad sarbecovirus neutralization by a human monoclonal antibody
Spike protein ACE2 Spike variant Cryo-EM Crystallization Novel compound Biophysical assay Protein factor Animal model In vitro Mechanism Antibody |
Vero E6 cells; Syrian hamsters; Various (VSV)Spike-pseudotyped viruses (including SARS-CoV-2 variants B.1.1.7, B.1.351. or P.1); modified live SARS-CoV-2 (based on 2019-nCoV/USA_WA1/2020) | 49.96 | The antibody bound Spike RBD of various sarbecovirus clades including SARS-CoV-2 in vitro. It neutralized several SARS-CoV-2 strains/mutants (including B.1.1.7, B.1.351, P.1 and B.1.429 variants of concern). It was shown to bind a cryptic epitope within RBD, thus blocking ACE2 binding. Only mutations in G504 of Spike were observed to generate an escape phenotype. The antibody reduced lung viral loads in a hamster model. Additive effect was observed with S309. |
Jul/19/2021 |
